Akorn and lenders negotiate its future again
Akorn Pharmaceuticals, whose finances unraveled after manufacturing issues bombed a $ 4.3 billion buyout by Fresenius, is back at the negotiating table with lenders who are keeping it afloat. In a two-sentence announcement, the Lake Forest, Illinois-based drugmaker Monday said that “negotiations with certain of its lenders are ongoing following the expiration of its standstill… Read More »